Epoprostenol-associated ascites in pulmonary arterial hypertension
PULMONARY CIRCULATION(2022)
摘要
The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre-existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the prostaglandin PGI(2).
更多查看译文
关键词
ascites, epoprostenol, pulmonary hypertension
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要